ReviewCancer communications (London, England)2025

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.

Jing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.